Enumeral Biomedical Holdings, Inc.

Common Stock SEC Reporting - Current
Verified Company Profile 8/23/2016
Contact Info
  • 200 CambridgePark Drive
  • Suite 2000
  • Cambridge, MA 02140

Business Description

Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Jun 30, 2016 10-Q
CIK 0001561551
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts
Wael Fayad President, CEO
Kevin G Sarney VP, Fin.
Company Directors
Wael Fayad Chairman
Barry Buckland
Robert J. Easton
Robert Van Nostrand
Allan Rothstein
Paul Sekhri
Arthur Tinkelenberg
Company Notes
  • Note = Incorporated in Nevada until 7-2014
  • Formerly=Cerulean Group, Inc. until 7-2014
Service Providers
Accounting/Auditing Firm
Friedman LLP
301 Lippincott Drive
4th Floor
Marlton, NJ, 08053
United States

Legal Counsel
Duane Morris LLP
1540 Broadway
New York, NY, 10036-4086
United States

Kevin A. Polis, Esq.
1540 Sixth Ave
San Diego, CA, United States

Investor Relations Firm
Not Available
ENUM Security Details
Share Structure
Market Value1 $9,373,227 a/o Oct 21, 2016
Authorized Shares 300,000,000 a/o Dec 31, 2015
Outstanding Shares 52,073,481 a/o Mar 24, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 5,880,314 a/o Feb 24, 2015
Par Value 0.001
Shareholders of Record 323 a/o Mar 30, 2016
Short Selling Data
Short Interest 7,055 (-32.28%)
Sep 15, 2016
Significant Failures to Deliver No

1Market Value calculated only for respective security